This abstract provides data on 57 patients who either received abiraterone + androgen deprivation therapy (ADT) or abiraterone alone for mCRPC. Unlike the abstract by Carsten H. Ohlmann, MD et al, this was a non-randomized, retrospective review of patients.



Presented by: Gautam Gopalji Jha, MBBS, MS, University of Minnesota, Minneapolis, MN
Written by: Jason Zhu, MD. Fellow, Division of Hematology and Oncology, Duke University, @TheRealJasonZhu at the 2019 ASCO Annual Meeting #ASCO19, May 31- June 4, 2019, Chicago, IL USA
References:
- De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine 2011;364:1995-2005.
- Ryan CJ, Smith MR, De Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine 2013;368:138-48.